Bellerophon Therapeutics - BLPH Stock Forecast, Price & News

0 brokerages have issued twelve-month price objectives for Bellerophon Therapeutics' stock. Their BLPH share price forecasts range from $19.00 to $19.00. On average, they predict the company's share price to reach $19.00 in the next twelve months. This suggests a possible upside of 1,762.7% from the stock's current price.
View analysts price targets for BLPH or view top-rated stocks among Wall Street analysts.

Bellerophon Therapeutics' stock was trading at $3.10 at the beginning of 2022. Since then, BLPH shares have decreased by 67.1% and is now trading at $1.02.
View the best growth stocks for 2022 here.

Bellerophon Therapeutics saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 17,600 shares, a decrease of 36.9% from the October 31st total of 27,900 shares. Based on an average trading volume of 14,800 shares, the days-to-cover ratio is currently 1.2 days. Currently, 0.2% of the shares of the stock are short sold.
View Bellerophon Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 30th 2023.
View our BLPH earnings forecast.

Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) issued its quarterly earnings results on Monday, November, 15th. The biotechnology company reported ($0.49) EPS for the quarter, topping analysts' consensus estimates of ($0.63) by $0.14.

Bellerophon Therapeutics's stock reverse split on Monday, February 10th 2020. The 1-15 reverse split was announced on Friday, February 7th 2020. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 7th 2020. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Bellerophon Therapeutics investors own include Inovio Pharmaceuticals (INO), Vaxart (VXRT), Corbus Pharmaceuticals (CRBP), Novavax (NVAX), Pfizer (PFE), Verastem (VSTM), Gilead Sciences (GILD), OPKO Health (OPK), SCYNEXIS (SCYX) and Dynavax Technologies (DVAX).

(BLPH) raised $60 million in an initial public offering on Friday, February 13th 2015. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Leerink Partners and Cowen and Company served as the underwriters for the IPO and FBR and SunTrust Robinson Humphrey were co-managers.

Bellerophon Therapeutics trades on the NASDAQ under the ticker symbol "BLPH."

Bellerophon Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (3.62%), Renaissance Technologies LLC (2.06%) and Telemetry Investments L.L.C. (0.50%). Insiders that own company stock include New Mountain Investments Ii, L and Wassim Fares.
View institutional ownership trends.

Shares of BLPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BLPH stock can currently be purchased for approximately $1.02.

Bellerophon Therapeutics (NASDAQ:BLPH) has a market capitalization of $9.74 million. The biotechnology company earns $-17,760,000.00 in net income (profit) each year or ($2.00) on an earnings per share basis.

Bellerophon Therapeutics' mailing address is 184 LIBERTY CORNER ROAD SUITE 302, WARREN NJ, 07059. The official website for the company is www.bellerophon.com. The biotechnology company can be reached via phone at (908) 574-4770 or via email at btinvestorrelations@bellerophon.com.